PL2155243T4 - Kompozycje i sposoby zawierające antygeny KLK3, PSCA lub FOLH1 - Google Patents

Kompozycje i sposoby zawierające antygeny KLK3, PSCA lub FOLH1

Info

Publication number
PL2155243T4
PL2155243T4 PL08754370T PL08754370T PL2155243T4 PL 2155243 T4 PL2155243 T4 PL 2155243T4 PL 08754370 T PL08754370 T PL 08754370T PL 08754370 T PL08754370 T PL 08754370T PL 2155243 T4 PL2155243 T4 PL 2155243T4
Authority
PL
Poland
Prior art keywords
klk3
psca
compositions
methods
folh1
Prior art date
Application number
PL08754370T
Other languages
English (en)
Other versions
PL2155243T3 (pl
Inventor
Yvonne Paterson
John Rothman
Vafa Shahabi
Original Assignee
Univ Pennsylvania
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Advaxis Inc filed Critical Univ Pennsylvania
Publication of PL2155243T3 publication Critical patent/PL2155243T3/pl
Publication of PL2155243T4 publication Critical patent/PL2155243T4/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08754370T 2007-05-10 2008-05-12 Kompozycje i sposoby zawierające antygeny KLK3, PSCA lub FOLH1 PL2155243T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/798,177 US9012141B2 (en) 2000-03-27 2007-05-10 Compositions and methods comprising KLK3 of FOLH1 antigen
PCT/US2008/006048 WO2008140812A2 (en) 2007-05-10 2008-05-12 Compositions and methods comprising klk3, psca, or folh1 antigen
EP08754370.8A EP2155243B8 (en) 2007-05-10 2008-05-12 Compositions and methods comprising klk3, psca, or folh1 antigen

Publications (2)

Publication Number Publication Date
PL2155243T3 PL2155243T3 (pl) 2015-08-31
PL2155243T4 true PL2155243T4 (pl) 2015-08-31

Family

ID=38648573

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08754370T PL2155243T4 (pl) 2007-05-10 2008-05-12 Kompozycje i sposoby zawierające antygeny KLK3, PSCA lub FOLH1

Country Status (10)

Country Link
US (4) US9012141B2 (pl)
EP (2) EP2155243B8 (pl)
JP (3) JP2010526533A (pl)
DK (1) DK2155243T3 (pl)
ES (1) ES2531967T3 (pl)
HU (1) HUE024509T2 (pl)
PL (1) PL2155243T4 (pl)
PT (1) PT2155243E (pl)
SI (1) SI2155243T1 (pl)
WO (1) WO2008140812A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003102168A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20100196336A1 (en) * 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8241636B2 (en) * 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5757863B2 (ja) * 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2010099318A1 (en) * 2009-02-27 2010-09-02 Yale University Physiologic sample preparation for nanosensors
US9739771B2 (en) 2009-02-27 2017-08-22 Yale University Physiologic sample preparation for nanosensors
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
CA2947358A1 (en) 2014-02-18 2015-08-27 Advaxis, Inc. Biomarker directed multi-target immunotherapy
AU2015250111A1 (en) 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2017030956A1 (en) * 2015-08-14 2017-02-23 Agenus Inc. Method of inducing a t-cell response to phosphopeptides using nucleic acids encoding phosphopeptide mimetics
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
EP3491009A4 (en) * 2016-08-01 2020-03-04 Aduro BioTech, Inc. Protein expression enhancer sequences and use thereof
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
JP7284156B2 (ja) * 2017-09-19 2023-05-30 アドバクシス， インコーポレイテッド 細菌またはＬｉｓｔｅｒｉａ株の凍結乾燥のための組成物および方法
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US12702681B2 (en) 2018-08-02 2026-08-11 Suzhou Royaltech Med Co., Ltd Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1156953A (en) * 1979-06-08 1983-11-15 Research Council Of Alberta Lime addition to heavy crude oils prior to coking
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
FR2686896B1 (fr) 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US20070264279A1 (en) 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US6017705A (en) * 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
ATE312934T1 (de) 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
DE19541450C2 (de) * 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Genkonstrukt und dessen Verwendung
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5858682A (en) * 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
JP4404381B2 (ja) 1997-03-10 2010-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐｓｃａ：前立腺幹細胞抗原
KR20050084537A (ko) 1997-04-17 2005-08-26 세키스이가가쿠 고교가부시키가이샤 도전성 미립자의 제조장치
ES2253789T3 (es) 1997-04-18 2006-06-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Cepa de salmonella atenuada usada como vehiculo para inmunizacion oral.
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
AU3710597A (en) 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US6818002B2 (en) * 1999-02-02 2004-11-16 Samuel Shiber Vessel cleaner and barrier
EP1159429A2 (en) * 1999-02-18 2001-12-05 Compugen Ltd. Psa and klk-2 splicing variants
DE19949594A1 (de) 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7199229B2 (en) * 2000-08-11 2007-04-03 Mount Sinai Hospital Kallikrein gene
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
CA2466845A1 (en) 2001-11-21 2003-06-05 Fred Ramsdell Manipulation of cytokine levels using cd83 gene products
JP2006502964A (ja) * 2002-02-06 2006-01-26 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 特定の器官または組織に対する全身性免疫応答の標的化のための方法および組成物
US20030219802A1 (en) 2002-03-08 2003-11-27 The Regents Of The University Of Michigan Diagnosis and treatment of osteosarcoma
JP2005519606A (ja) * 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2004204751A1 (en) 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
KR20060130038A (ko) 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 ＥｐｈＡ２ 백신
WO2005052593A1 (en) * 2003-10-29 2005-06-09 The University Of Leicester Detection
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CA2551644C (en) 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
CN100549021C (zh) * 2004-05-27 2009-10-14 森托科尔公司 猕猴前列腺特异性抗原
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
ES2543079T3 (es) 2004-08-13 2015-08-14 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia antibiótica
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
EP1846041A4 (en) * 2004-10-29 2008-05-07 Univ Rochester MODIFIED BACTERIOPHAGE VECTORS AND ITS USES
EP1828145A4 (en) * 2004-12-10 2009-08-19 Univ Emory 2'- AND 3'-SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRAL INFECTIONS AND ANORMAL CELL PROLIFERATION
WO2007061848A2 (en) 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
RU2006112025A (ru) 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
GB2451014B (en) 2006-03-01 2010-12-29 Anza Therapeutics Inc Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2007137258A2 (en) 2006-05-22 2007-11-29 New York University C-glycolipids with enhanced th-1 profile
ES2372709T3 (es) * 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
WO2008008311A1 (en) 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8241636B2 (en) 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
DE102006051171A1 (de) * 2006-10-26 2008-04-30 Sms Demag Ag Stranggießkokille
EP2147092A4 (en) 2007-04-16 2010-06-09 Univ Pennsylvania ANTIBIOTIC RESISTANCE-FREE LISTERIA TRIBES AND METHOD OF CONSTRUCTING AND USING THEREOF
WO2009110950A1 (en) 2007-12-31 2009-09-11 The Trustees Of The University Of Pennsylvania Attenuated listeria strain and adenovirus strain vaccines and methods of use
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
KR20110045010A (ko) 2008-07-24 2011-05-03 아두로 바이오테크 Ｃ형 간염의 치료를 위한 조성물 및 방법
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP5985397B2 (ja) 2009-11-11 2016-09-06 アドバクシス インコーポレイテッド 組換えリステリア株およびそれを含む免疫原性組成物
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
JP2013219162A (ja) * 2012-04-09 2013-10-24 Sharp Corp 合わせガラス構造太陽電池モジュール
CA2947358A1 (en) 2014-02-18 2015-08-27 Advaxis, Inc. Biomarker directed multi-target immunotherapy
AU2015223136A1 (en) 2014-02-25 2016-09-22 Advaxis, Inc. Compositions and methods for the treatment of HER2/Neu over-expressing tumors
SG11201607213QA (en) 2014-03-05 2016-09-29 Advaxis Inc Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
AU2015250111A1 (en) 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
SG11201609135VA (en) 2014-05-02 2016-11-29 Univ Pennsylvania Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
EP3169356A4 (en) 2014-07-18 2018-03-28 Advaxis, Inc. Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
WO2016011320A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
CN106794235A (zh) 2014-07-18 2017-05-31 阿德瓦希斯公司 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
SG11201702857PA (en) 2014-10-14 2017-05-30 Univ Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
WO2016126878A2 (en) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Listeria-based immunomodulation
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126876A2 (en) 2015-02-03 2016-08-11 Advaxis, Inc. Listeria-based adjuvants
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
US20180104284A1 (en) 2015-05-13 2018-04-19 Advaxis, Inc. Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof
TW201708536A (zh) 2015-05-26 2017-03-01 艾法西斯公司 個人化的基於遞送載體之免疫療法及其用途
EP3313975A4 (en) 2015-06-24 2019-03-13 Advaxis, Inc. MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY
WO2017048850A1 (en) 2015-09-15 2017-03-23 Advaxis, Inc. Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment
MA42841A (fr) 2015-09-15 2018-07-25 Advaxis Inc Procédé de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria de recombinaison
JP2018527382A (ja) 2015-09-17 2018-09-20 アドバクシス， インコーポレイテッド 組み換え型リステリアワクチン株および癌免疫療法におけるその使用方法
AU2016340148A1 (en) 2015-10-14 2018-05-31 Advaxis, Inc. Recombinant Listeria strains and methods of using the same in cancer immunotherapy
US20180325964A1 (en) 2015-11-20 2018-11-15 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
TW201726171A (zh) 2015-12-16 2017-08-01 艾法西斯公司 以李斯特菌屬為主的免疫治療及其用法
CA3012829A1 (en) 2016-01-27 2017-08-03 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
CA3029235A1 (en) 2016-07-05 2018-01-11 Advaxis, Inc. Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof
MA46721A (fr) 2016-11-07 2019-09-11 Advaxis Inc Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
WO2018129306A1 (en) 2017-01-05 2018-07-12 Advaxis, Inc. Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
WO2018170313A1 (en) 2017-03-16 2018-09-20 Advaxis, Inc. Methods and compositions for increasing efficacy of vaccines
WO2019006401A2 (en) 2017-06-30 2019-01-03 Advaxis, Inc. LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
JP7284156B2 (ja) 2017-09-19 2023-05-30 アドバクシス， インコーポレイテッド 細菌またはＬｉｓｔｅｒｉａ株の凍結乾燥のための組成物および方法
US20210177955A1 (en) 2017-11-08 2021-06-17 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
US20210003558A1 (en) 2018-03-09 2021-01-07 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of listeria strains
EP3785029A1 (en) 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics

Also Published As

Publication number Publication date
SI2155243T1 (sl) 2015-06-30
PL2155243T3 (pl) 2015-08-31
EP2155243B1 (en) 2014-12-03
DK2155243T3 (en) 2015-03-09
JP2016187340A (ja) 2016-11-04
US9549973B2 (en) 2017-01-24
WO2008140812A3 (en) 2009-02-05
HUE024509T2 (en) 2016-01-28
US20070253976A1 (en) 2007-11-01
US11446369B2 (en) 2022-09-20
JP5932751B2 (ja) 2016-06-08
PT2155243E (pt) 2015-03-30
EP2859899A1 (en) 2015-04-15
WO2008140812A2 (en) 2008-11-20
US20170100469A1 (en) 2017-04-13
US20150335721A1 (en) 2015-11-26
EP2155243A2 (en) 2010-02-24
JP2010526533A (ja) 2010-08-05
JP2014064569A (ja) 2014-04-17
ES2531967T3 (es) 2015-03-23
EP2155243B8 (en) 2015-02-18
US20200069785A1 (en) 2020-03-05
EP2155243A4 (en) 2011-07-27
US9012141B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
PL2155243T3 (pl) Kompozycje i sposoby zawierające antygeny KLK3, PSCA lub FOLH1
HRP20180596T1 (hr) PROTUTIJELA PROTIV Sp35 I NJIHOVA UPOTREBA
IL217278A0 (en) Nucleic acid - lipid particles, compositions comprising the same and uses thereof
IL208744A0 (en) Nucleic acid-lipid particles, compositions comprising the same and uses thereof
IL186965A0 (en) Anti-il-6 antibodies, compositions, methods and uses
EP2043687A4 (en) ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
ZA201002313B (en) Human antibodies that bind mesothelin,and uses thereof
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
IL193392A0 (en) Influenza antibodies, compositions, and related methods
ZA201003427B (en) Human anti-amyloid antibodies,compositions,methods and uses
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
IL219801A0 (en) ANTI-C4.4a ANTIBODIES AND USES THEREOF
EP2195328A4 (en) PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
EP2205276A4 (en) ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
EP2139478A4 (en) CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
GB0706077D0 (en) Methods, Compositions and uses thereof
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
GB0616111D0 (en) Agents, methods and uses
IL202996A0 (en) Anti-mcp-1 antibodies, compositions, methods and uses
GB0703763D0 (en) Bone-replacement materials,methods and devices
AU2013201278A1 (en) Sp35 Antibodies and Uses Thereof